Written by : Nikita Saha
February 3, 2025
This expanded partnership will introduce next-generation AI-driven solutions, allowing Gilead to further optimize its operations while continuing its mission to develop life-saving medicines for cancer, HIV, and other life-threatening diseases.
Cognizant has announced an expansion of its long-standing partnership with Gilead Sciences. The partnership aims to leverage artificial intelligence (AI) and machine learning (ML) to drive greater efficiency and cost leadership.
The extended collaboration seeks to enhance Gilead’s digital transformation efforts, improving customer service, employee interactions, and overall business value management.
For over a decade, Cognizant has played a crucial role in supporting Gilead’s global IT infrastructure, platforms, applications, and advanced analytics.
This expanded partnership will introduce next-generation AI-driven solutions, allowing Gilead to further optimize its operations while continuing its mission to develop life-saving medicines for cancer, HIV, and other life-threatening diseases.
By utilizing Cognizant’s expertise in AI and advanced technology applications, Gilead aims to unlock new efficiencies across its value chain.
The partnership will integrate generative AI within an agentic framework to automate multiple business functions, delivering improved productivity and enhanced financial structures.
Cognizant plans to deploy its Neuro AI generative AI platform, designed to accelerate value creation and transform IT and business operations.
This initiative will introduce custom-built AI solutions tailored to enhance Gilead’s operational efficiency, streamline IT services, and drive cost savings.
According to Joydeep Ganguly, Senior Vice President & Head of Corporate Operations and Interim CIO at Gilead, this partnership is a key milestone in the company’s technology evolution.
He emphasized that Cognizant’s expertise will be instrumental in driving a new level of cost leadership while advancing Gilead’s capabilities roadmap.
Cognizant executives expressed their commitment to helping Gilead optimize its digital transformation journey.
Surya Gummadi, Executive Vice President and President of Cognizant Americas, highlighted that this expanded agreement will focus on enhancing user engagement, productivity, and cost efficiencies.
"Our teams will work together to transform user engagement, boost productivity, and maximize cost savings, allowing Gilead to focus on its core mission—developing and delivering life-saving treatments," said Gummadi.
Additionally, Mohammad Haque, Senior Vice President and Global Large Deals Lead at Cognizant, emphasized the role of Cognizant’s premier managed services frameworks and automation tools in driving operational efficiencies.
"We aim to provide end-to-end digital transformation solutions to help Gilead extract maximum value from its technology investments," Haque added.
Stay tuned for more such updates on Digital Health News.